NeuShen Therapeutics notes closure of pre-A financing round led by LAMPAM Capital.
AN2 Therapeutics said the base period contract is $4.3 million with additional options that, if exercised, will total $17.8 million to support preclinical, Phase 1 studies and other activities to enable advancement of epetraborole into a pivotal Phase 2/3 clinical trial for acute systemic melioidosis.
Recently rebranded careviso is scaling its technology and offerings to remove the administrative barriers associated with prior authorizations and financial transparency for diagnostic testing. Technology provides enhanced outcomes and transparency for patients and physicians alike.
Anebulo Pharmaceuticals anticipates using the net proceeds from the private placement to advance the development of ANEB-001 and for other general corporate purposes.
TAU Systems to Build a New Generation of Compact Particle Accelerators Following $15M Seed Investment
TAU Systems is poised to bring particle accelerators to a multitude of users by harnessing the latest laser technology to make electrons surf on three-dimensional plasma waves and accelerate them to ultra-high energies.
NIH Awards Matregenix a Phase 1 SBIR Grant to Develop a New Dental Barrier Membrane for Guided Bone Regeneration
Guided bone regeneration (GBR) is a common technique used in the dental industry for the treatment of bony defects, among other conditions.